43 results on '"Gulley, James L."'
Search Results
2. Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.
- Author
-
Gulley, James L., Repasky, Elizabeth A., Wood, Laura S., and Butterfield, Lisa H.
- Subjects
- *
CANCER treatment , *IMMUNOTHERAPY , *CONFERENCES & conventions ,CANCER associations - Abstract
Therapeutic efforts to engage the immune system against cancer have yielded exciting breakthroughs and a growing list of approved immune-based agents across a variety of disease states. Despite the early successes and durable responses associated with treatments such as immune checkpoint inhibition, there is still progress to be made in the field of cancer immunotherapy. The 31st annual meeting of the Society for Immunotherapy of Cancer (SITC 2016), which took place November 11–13, 2016 in National Harbor, Maryland, showcased the latest advancements in basic, translational, and clinical research focused on cancer immunology and immunotherapy. Novel therapeutic targets, insights into the dynamic tumor microenvironment, potential biomarkers, and novel combination approaches were some of the main themes covered at SITC 2016. This report summarizes key data and highlights from each session. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.
- Author
-
Gulley, James L., Madan, Ravi A., Pachynski, Russell, Mulders, Peter, Sheikh, Nadeem A., Trager, James, and Drake, Charles G.
- Subjects
- *
CANCER immunotherapy , *ANTIGENS , *CANCER cells , *IMMUNE response , *ANTIGENIC drift , *TUMOR treatment , *CELLULAR immunity , *IMMUNOTHERAPY , *TIME , *TUMOR antigens , *TUMORS , *ANTIBODY formation - Abstract
Immunotherapy is an important breakthrough in cancer. US Food and Drug Administration-approved immunotherapies for cancer treatment (including, but not limited to, sipuleucel-T, ipilimumab, nivolumab, pembrolizumab, and atezolizumab) substantially improve overall survival across multiple malignancies. One mechanism of action of these treatments is to induce an immune response against antigen-bearing tumor cells; the resultant cell death releases secondary (nontargeted) tumor antigens. Secondary antigens prime subsequent immune responses (antigen spread). Immunotherapy-induced antigen spread has been shown in clinical studies. For example, in metastatic castration-resistant prostate cancer patients, sipuleucel-T induced early immune responses to the immunizing antigen (PA2024) and/or the target antigen (prostatic acid phosphatase). Thereafter, most patients developed increased antibody responses to numerous secondary proteins, several of which are expressed in prostate cancer with functional relevance in cancer. The ipilimumab-induced antibody profile in melanoma patients shows that antigen spread also occurs with immune checkpoint blockade. In contrast to chemotherapy, immunotherapy often does not result in short-term changes in conventional disease progression end points (eg, progression-free survival, tumor size), which may be explained, in part, by the time taken for antigen spread to occur. Thus, immune-related response criteria need to be identified to better monitor the effectiveness of immunotherapy. As immunotherapy antitumor effects take time to evolve, immunotherapy in patients with less advanced cancer may have greater clinical benefit vs those with more advanced disease. This concept is supported by prostate cancer clinical studies with sipuleucel-T, PSA-TRICOM, and ipilimumab. We discuss antigen spread with cancer immunotherapy and its implications for clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Immunotherapy biomarkers 2016: overcoming the barriers.
- Author
-
Gulley, James L., Berzofsky, Jay A., Butler, Marcus O., Cesano, Alessandra, Fox, Bernard A., Gnjatic, Sacha, Janetzki, Sylvia, Kalavar, Shyam, Karanikas, Vaios, Khleif, Samir N., Kirsch, Ilan, Lee, Peter P., Maccalli, Cristina, Maecker, Holden, Schlom, Jeffrey, Seliger, Barbara, Siebert, Janet, Stroncek, David F., Thurin, Magdalena, and Yuan, Jianda
- Subjects
- *
IMMUNOTHERAPY , *CANCER treatment , *CONFERENCES & conventions - Abstract
This report summarizes the symposium, 'Immunotherapy Biomarkers 2016: Overcoming the Barriers', which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cosponsored by the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI), focused on emerging immunotherapy biomarkers, new technologies, current hurdles to further progress, and recommendations for advancing the field of biomarker development. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?
- Author
-
Bilusic, Marijo and Gulley, James L
- Subjects
- *
LUMPECTOMY , *LIMB salvage , *BLADDER cancer , *IMMUNOTHERAPY , *REGULATORY T cells , *IMMUNE checkpoint inhibitors , *OVERALL survival , *TRIPLE-negative breast cancer , *IMMUNOLOGICAL adjuvants , *COMBINED modality therapy - Published
- 2021
- Full Text
- View/download PDF
6. Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses.
- Author
-
Larkin, Riley M., Lopez, Diana C., Robbins, Yvette L., Lassoued, Wiem, Canubas, Kenneth, Warner, Andrew, Karim, Baktiar, Vulikh, Ksenia, Hodge, James W., Floudas, Charalampos S., Gulley, James L., Gallia, Gary L., Allen, Clint T., and London Jr., Nyall R.
- Subjects
- *
NEUROBLASTOMA , *MYELOID-derived suppressor cells , *KILLER cells , *HLA-DR antigens , *CHEMOKINES , *SKULL base - Abstract
Background: Olfactory neuroblastoma is a rare malignancy of the anterior skull base typically treated with surgery and adjuvant radiation. Although outcomes are fair for low-grade disease, patients with high-grade, recurrent, or metastatic disease oftentimes respond poorly to standard treatment methods. We hypothesized that an in-depth evaluation of the olfactory neuroblastoma tumor immune microenvironment would identify mechanisms of immune evasion in high-grade olfactory neuroblastoma as well as rational targetable mechanisms for future translational immunotherapeutic approaches. Methods: Multispectral immunofluorescence and RNAScope evaluation of the tumor immune microenvironment was performed on forty-seven clinically annotated olfactory neuroblastoma samples. A retrospective chart review was performed and clinical correlations assessed. Results: A significant T cell infiltration was noted in olfactory neuroblastoma samples with a stromal predilection, presence of myeloid-derived suppressor cells, and sparse natural killer cells. A striking decrease was observed in MHC-I expression in high-grade olfactory neuroblastoma compared to low-grade disease, representing a mechanism of immune evasion in high-grade disease. Mechanistically, the immune effector stromal predilection appears driven by low tumor cell MHC class II (HLA-DR), CXCL9, and CXCL10 expression as those tumors with increased tumor cell expression of each of these mediators correlated with significant increases in T cell infiltration. Conclusion: These data suggest that immunotherapeutic strategies that augment tumor cell expression of MHC class II, CXCL9, and CXCL10 may improve parenchymal trafficking of immune effector cells in olfactory neuroblastoma and augment immunotherapeutic responses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment.
- Author
-
Madan, Ravi A and Gulley, James L
- Subjects
- *
CASTRATION-resistant prostate cancer , *ABIRATERONE acetate , *IPILIMUMAB , *PROSTATE cancer - Abstract
An editorial is presented on the clinical trials with immune checkpoint inhibitors for finding the best possible treatment for prostate cancer. Topics discussed include inhospitability to immune cells which limits the potential of immunotherapy in prostate cancer, data analysis in gene expression to improve immunotherapy development and treatment of prostate cancer patient with ipilimumab.
- Published
- 2019
- Full Text
- View/download PDF
8. Immunologic Monitoring of Cellular Immune Responses in Cancer Vaccine Therapy.
- Author
-
Whiteside, Theresa L., Gulley, James L., Clay, Timothy M., and Kwong Yok Tsang
- Abstract
The authors reflect on the importance of cellular immune responses to the immunotherapy for cancer that aims to induce the antigen-specific T cells in the immune system. They cite the need to monitor the cellular immune responses for the development of potential vaccines against specific cancer. The authors believe that the immune monitoring assays in current trials have limited usefulness as surrogate markers of clinical effectiveness.
- Published
- 2011
- Full Text
- View/download PDF
9. Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot".
- Author
-
Bilusic, Marijo and Gulley, James L
- Subjects
- *
IMMUNOLOGICAL adjuvants , *IMMUNOTHERAPY , *TUMORS - Published
- 2017
- Full Text
- View/download PDF
10. Toward an off-the-shelf vaccine for B-cell malignancies.
- Author
-
Gulley, James L.
- Subjects
- *
B cell lymphoma , *ANTIGENS , *ANTI-idiotypic vaccines , *LYMPHOMAS - Abstract
In this article, the author comments on an article by J. Weng on the application of an off-the-shelf approach targeting a common antigen on malignant B cells while idiotype vaccines have shown promise for B-cell malignancies. The potential for an off-the-shelf vaccine for lymphomas is offered by the identification of a common antigen on B-cell malignancies that is not present on normal B cells.
- Published
- 2012
- Full Text
- View/download PDF
11. Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm.
- Author
-
Gulley, James L., Mulders, Peter, Albers, Peter, Banchereau, Jacques, Bolla, Michel, Pantel, Klaus, and Powles, Thomas
- Subjects
- *
SIPULEUCEL-T (Drug) , *PROSTATE cancer treatment , *IMMUNOTHERAPY , *IMMUNE response , *PROSTATE cancer patients , *THERAPEUTICS - Abstract
Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to extend survival. As an immunotherapy, sipuleucel-T possesses specific characteristics differentiating it from traditional therapies. At a roundtable meeting of experts, sipuleucel-T data were discussed, focusing on interpretation and clinical implications. Important differences between immunotherapies and traditional therapies were explored, e.g., mode of action, outcomes, data consistency and robustness, timing of sipuleucel-T treatment, and future perspectives in areas such as short-term markers of long-term benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. (R)Evolutionary Therapy: The Potential of Immunotherapy to Fulfill the Promise of Personalized Cancer Treatment.
- Author
-
Madan, Ravi A. and Gulley, James L.
- Subjects
- *
ONCOLOGY research , *INDIVIDUALIZED medicine , *CANCER research , *CANCER chemotherapy , *CANCER treatment - Abstract
Since the millennium, personalized medicine has been at the forefront of therapeutic endeavors in medical oncology. The latest technology has given researchers the ability to define cancer at its molecular core. This has led to the development of “targeted therapies,” designed to eliminate driver mutations while leaving healthy cells unscathed. Unfortunately, more than 10 years into the targeted molecular therapy era, successes have been infrequent, and toxicity remains largely unchanged compared with relatively indiscriminant, traditional chemotherapy. Emerging data suggests that the malignant clonal heterogeneity within solid tumors is so diverse that targeting one or even several mutations is likely to have minimal, transient impact. In recent years, new therapies have emerged that can effectively stimulate the immune system and improve survival in patients with metastatic disease. Through immune activation, there is the potential to target the cancer with a biologic diversity that can potentially rival the multiplicity of malignant mutations within tumors. Stimulating the immune system to become an evolving adversary against malignant cells may revolutionize cancer therapy in the years to come. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
13. Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer.
- Author
-
GULLEY, JAMES L., LEITMANWILLIAM, SUSAN F., and SCHLOM, DAHUTJEFFREY
- Subjects
- *
LETTERS to the editor , *IMMUNOTHERAPY - Abstract
A letter to the editor is presented in response to the article "Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer," by M. L. Huber and colleagues.
- Published
- 2012
- Full Text
- View/download PDF
14. Immunologic monitoring of cellular immune responses in cancer vaccine therapy.
- Author
-
Whiteside, Theresa L, Gulley, James L, Clay, Timothy M, and Tsang, Kwong Yok
- Published
- 2011
15. Immunologic and Prognostic Factors Associated with Overall Survival Employing a Poxviral-based PSA Vaccine in Metastatic Castrate-resistant Prostate Cancer.
- Author
-
Gulley, James L., Arlen, Philip M., Madan, Ravi A., Kwong-Yok Tsang, Pazdur, Mary P., Skarupa, Lisa, Jones, Jacquin L., Poole, Diane J., Higgins, Jack P., Hodge, James W., Cereda, Vittore, Vergati, Matteo, Steinberg, Seth M., Halabi, Susan, Jones, Elizabeth, Chen, Clara, Parnes, Howard, Wright, John J., Dahut, William L., and Schlom, Jeffrey
- Abstract
A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p = 0.0061) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The study reported here employed the identical vaccine in mCRPC to investigate the influence of GM-CSF with vaccine, and the influence of immunologic and prognostic factors on median OS. Thirty-two patients were vaccinated once with recombinant vaccinia containing the transgenes for prostate-specific antigen (PSA) and three costimulatory molecules. Patients received boosters with recombinant fowlpox containing the same four transgenes. Twelve of 32 patients showed declines in serum PSA post-vaccination and 2/12 showed decreases in index lesions. Median OS was 26.6 months (predicted median OS by the Halabi nomogram was 17.4 months). Patients with greater PSA-specific T-cell responses showed a trend (p = 0.055) toward enhanced survival. There was no difference in T-cell responses or survival in cohorts of patients receiving GM-CSF versus no GM-CSF. Patients with a Halabi predicted survival of <18 months (median predicted 12.3 months) had an actual median OS of 14.6 months, while those with a Halabi predicted survival of ≥18 months (median predicted survival 20.9 months) will meet or exceed 37.3 months, with 12/15 patients living longer than predicted (p = 0.035). Treg suppressive function was shown to decrease following vaccine in patients surviving longer than predicted, and increase in patients surviving less than predicted. This hypothesis-generating study provides evidence that patients with more indolent mCRPC (Halabi predicted survival ≥18 months) may best benefit from vaccine therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer.
- Author
-
Tucker, Jo A., Jochems, Caroline, Gulley, James L., Jeffrey Schlom, and Tsang, Kwong Y.
- Subjects
- *
CANCER vaccines , *TISSUE extracts , *IMMUNOTHERAPY , *IPILIMUMAB , *IMMUNOLOGICAL tolerance , *KILLER cells , *PROSTATE tumors , *T cells , *THERAPEUTICS , *VACCINES - Abstract
Active immunotherapy is dependent on the ability of the immune system to recognize and respond to tumors. Despite overwhelming evidence to support a cell-mediated immune response to prostate cancer, it is insufficient to eradicate the disease. This is likely due to a high level of suppression at the tumor site from a variety of sources, including immunosuppressive cells. Immune cells entering the tumor microenvironment may be inhibited directly by the tumor, stromal cells or other immune cells that have been induced to adopt a suppressive phenotype. The resurgence of interest in immunotherapy following the approval of sipuleucel-T and ipilimumab by the Food and Drug Administration has brought about new strategies for overcoming tumor-mediated suppression and bolstering anti-tumor responses. Improved understanding of the immune response to prostate cancer can lead to new combination therapies, such as the use of vaccine with small molecule and checkpoint inhibitors or other immunotherapies. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
17. The role of soluble CD40L in immunosuppression.
- Author
-
Schlom, Jeffrey, Jochems, Caroline, Gulley, James L., and Huang, Jianping
- Subjects
- *
CD40 antigen , *IMMUNOSUPPRESSION , *CANCER treatment , *CANCER patients , *VACCINES - Abstract
We have recently performed the first comprehensive study of the potential immunosuppressive role of soluble CD40L (sCD40L). In addition, we demonstrated that serum sCD40L can potentially be used as an indicator of response to anticancer therapy, and/or to better identify those patients who would have best chances to benefit from tumortargeting vaccines or other therapeutic modalities. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
18. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
- Author
-
Madan, Ravi A, Antonarakis, Emmanuel S, Drake, Charles G, Fong, Lawrence, Yu, Evan Y, McNeel, Douglas G, Lin, Daniel W, Chang, Nancy N, Sheikh, Nadeem A, Gulley, James L, and Antonarakis, Emmanual S
- Subjects
- *
IMMUNE checkpoint inhibitors , *PROSTATE-specific antigen , *CASTRATION-resistant prostate cancer , *BIOCHEMICAL mechanism of action , *ABIRATERONE acetate , *IMMUNOLOGIC memory , *ACID phosphatase , *PROSTATE tumors treatment , *RESEARCH , *CLINICAL trials , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *IMPACT of Event Scale , *CANCER vaccines , *TISSUE extracts , *PROSTATE tumors - Abstract
Sipuleucel-T is an autologous cellular immunotherapy that induces an immune response targeted against prostatic acid phosphatase (PAP) to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. In the phase III IMPACT study, sipuleucel-T was associated with a statistically significantly increased overall survival (OS) (median = 4.1 months) vs placebo. Patients with baseline prostate-specific antigen levels in the lowest quartile (≤22.1 ng/mL) exhibited a 13-month improvement in OS with sipuleucel-T. Together, this led sipuleucel-T to be approved and recommended as first-line therapy in various guidelines for treatment of metastatic castration-resistant prostate cancer. This review discusses the varied findings about the mechanisms of action of sipuleucel-T, bringing them together to form a more coherent picture. These pieces include inducing a statistically significant increase in antigen-presenting cell activation; inducing a peripheral immune response specific to the target (PAP) and/or immunizing (PA2024) antigens; stimulating systemic cytotoxic T-lymphocyte activity; and mediating antigen spread (ie, increased antibody responses to secondary proteins in addition to PAP and PA2024). Each of these pieces individually correlates with OS. Sipuleucel-T also traffics T cells to the prostate and is associated with long-term immune memory such that a second course of treatment induces an anamnestic immune response. Prostate cancer does not have a strongly inflamed microenvironment, thus its response to immune checkpoint inhibitors is limited. Because sipuleucel-T is able to traffic T cells to the tumor, it may be an ideal combination partner with immunotherapies including immune checkpoint inhibitors or with radiation therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
- Author
-
Bilusic, Marijo, Heery, Christopher R., Collins, Julie M., Donahue, Renee N., Palena, Claudia, Madan, Ravi A., Karzai, Fatima, Marté, Jennifer L., Strauss, Julius, Gatti-Mays, Margaret E., Schlom, Jeffrey, and Gulley, James L.
- Subjects
- *
MONOCLONAL antibodies , *MYELOID-derived suppressor cells , *HYPOPHOSPHATEMIA , *ADVERSE health care events , *CHORDOMA , *THERAPEUTICS , *EPITHELIAL-mesenchymal transition - Abstract
Background: HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of myeloid-derived suppressor cells. Studies have demonstrated that high serum IL-8 levels correlate with poor prognosis in many malignant tumors. Preclinical studies have shown that IL-8 blockade may reduce mesenchymal features in tumor cells, making them less resistant to treatment. Methods: Fifteen patients with metastatic or unresectable locally advanced solid tumors were enrolled in this 3 + 3 dose-escalation trial at four dose levels (4, 8, 16, or 32 mg/kg). HuMax-IL8 was given IV every 2 weeks, and patients were followed for safety and immune monitoring at defined intervals up to 52 weeks. Results: All enrolled patients (five chordoma, four colorectal, two prostate, and one each of ovarian, papillary thyroid, chondrosarcoma, and esophageal) received at least one dose of HuMax-IL8. Eight patients had received three or more prior lines of therapy and five patients had received prior immunotherapy. Treatment-related adverse events occurred in five patients (33%), mostly grade 1. Two patients receiving the 32 mg/kg dose had grade 2 fatigue, hypophosphatemia, and hypersomnia. No dose-limiting toxicities were observed, and maximum tolerated dose was not reached. Although no objective tumor responses were observed, 11 patients (73%) had stable disease with median treatment duration of 24 weeks (range, 4--54 weeks). Serum IL-8 was significantly reduced on day 3 of HuMax-IL8 treatment compared to baseline (p = 0.0004), with reductions in IL-8 seen at all dose levels. Conclusions: HuMax-IL8 is safe and well-tolerated. Ongoing studies are evaluating the combination of IL-8 blockade and other immunotherapies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
- Author
-
Allen, Clint T., Lee, Sunmin, Norberg, Scott M., Kovalovsky, Damian, Hong Ye, Clavijo, Paul E., Hu-Lieskovan, Siwen, Schlegel, Richard, Schlom, Jeffrey, Strauss, Julius, Gulley, James L., Trepel, Jane, and Hinrichs, Christian S.
- Subjects
- *
PAPILLOMAVIRUS diseases , *HUMAN papillomavirus , *PROGRAMMED death-ligand 1 , *RESPIRATORY obstructions , *IMMUNE checkpoint proteins , *IMMUNE checkpoint inhibitors - Abstract
Background: Recurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV)-driven disorder that causes substantial morbidity and can lead to fatal distal airway obstruction and post-obstructive pneumonias. Patients require frequent surgical debridement of disease, and no approved systemic adjuvant therapies exist. Methods: A phase II study was conducted to investigate the clinical activity and safety of programmed deathligand 1 (PD-L1) blockade with avelumab in patients with RRP. Results: Twelve patients were treated. All patients with laryngeal RRP displayed improvement in disease burden, and 5 of 9 (56%) displayed partial responses. None of 4 patients with pulmonary RRP displayed a response. Using each patient's surgical history as their own control, patients required fewer surgical interventions after avelumab treatment (p = 0.008). A subset of partial responders developed HPV-specific reactivity in papilloma-infiltrating T-cells that correlated with reduced HPV viral load and an increased Tissue Inflammation Signature. Conclusions: Avelumab demonstrated safety and clinical activity in patients with laryngeal RRP. Further study of immune checkpoint blockade for RRP, possibly with longer treatment duration or in combination with other immunotherapies aimed at activating antiviral immunity, is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.
- Author
-
Keilholz, Ulrich, Mehnert, Janice M., Bauer, Sebastian, Bourgeois, Hugues, Patel, Manish R., Gravenor, Donald, Nemunaitis, John J., Taylor, Matthew H., Wyrwicz, Lucjan, Keun-Wook Lee, Kasturi, Vijay, Chin, Kevin, von Heydebreck, Anja, and Gulley, James L.
- Subjects
- *
ADVERSE health care events , *SURVIVAL rate , *DEATH rate , *PROGRESSION-free survival , *SKIN cancer , *MELANOMA - Abstract
Background: We report phase 1b data from patients enrolled in the JAVELIN Solid Tumor clinical trial (NCT01772004) with unresectable stage IIIC or IV melanoma that had progressed after ≥1 line of therapy for metastatic disease. Patients and methods: Patients received avelumab (10 mg/kg)--a human anti--PD-L1 antibody. Assessments included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Results: As of December 31, 2016, 51 patients were treated and followed for a median of 24.2months (range, 16.1-31.5). Most patients had cutaneous (n =28 [54.9%]) or ocular (n = 16 [31.4%]) melanoma and had received a median of 2 prior lines of therapy (range, 0-4), including ipilimumab (n = 26 [51.0%]). The confirmed ORR was 21.6% (95% CI, 11.3-35.3; complete response, 7.8%; partial response, 13.7%). The median duration of response was not estimable (95% CI, 2.6 months-not estimable). Median PFS and OS were 3.1 months (95% CI, 1.4-6.3) and 17.2 months (95% CI, 6.6-not estimable), respectively. Subgroup analyses suggested meaningful clinical activity (ORR [95% CI]) in patients with non-ocular melanoma (31.4% [16.9--49.3]), PD-L1--positive tumors (42.1% [20.3-66.5]), or prior ipilimumab therapy (30.8% [14.3--51.8]). Thirty-nine patients (76.5%) had a treatment-related adverse event (TRAE), most commonly infusion-related reaction (29.4%), fatigue (17.6%), and chills (11.8%); 4 patients (7.8%) had a grade 3 TRAE. Five patients (9.8%) had an immune-related TRAE (all were grade 1/2). No grade 4 TRAEs or treatment-related deaths were reported. Conclusion: Avelumab showed durable responses, promising survival outcomes, and an acceptable safety profile in patients with previously treated metastatic melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.
- Author
-
Redman, Jason M., Steinberg, Seth M., and Gulley, James L.
- Subjects
- *
CASTRATION-resistant prostate cancer , *IMMUNOTHERAPY - Abstract
Advances in immunotherapy utilizing immune checkpoint inhibitors (ICIs) have transformed the treatment landscapes of several malignancies in recent years. Oncologists are now tasked with extending these benefits to a greater number of patients and tumor types. Metastatic castration-resistant prostate cancer (mCRPC) infrequently responds to ICIs, while the cellular vaccine approved for mCRPC, sipuleucel-T, provides a 4-month survival benefit but does not produce clinical responses as monotherapy. However, many novel and generally well-tolerated immune oncology agents with potential for immune synergy and/or additive effects are undergoing clinical development. This availability presents opportunities to develop adaptive-design combination clinical trials aimed to generate, expand, and facilitate antitumor immune responses. Here we describe a currently accruing phase I/II trial (NCT03493945) testing a brachyury-targeted antitumor vaccine, TGF-β TRAP/anti-PD-L1 antibody, an IL-15 agonist, and an IDO1 inhibitor in mCRPC. Trial registration: This trial (NCT03493945) was registered in National Clinical Trials on April 11th 2018. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
- Author
-
Donahue, Renee N., Lepone, Lauren M., Grenga, Italia, Jochems, Caroline, Fantini, Massimo, Madan, Ravi A., Heery, Christopher R., Gulley, James L., and Schlom, Jeffrey
- Subjects
- *
MONOCLONAL antibodies , *ANTIBODY-dependent cell cytotoxicity , *CANCER treatment - Abstract
Background: Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) as a second potential mode of anti-tumor activity; the reason for this is the concern of lysis of PD-L1 positive immune cells. Avelumab is a fully human IgG1 MAb which has been shown in prior in vitro studies to mediate ADCC versus a range of human tumor cells, and clinical studies have demonstrated anti-tumor activity versus a range of human cancers. This study was designed to investigate the effect on immune cell subsets in the peripheral blood of cancer patients prior to and following multiple administrations of avelumab. Methods: One hundred twenty-three distinct immune cell subsets in the peripheral blood of cancer patients (n = 28) in a phase I trial were analyzed by flow cytometry prior to and following one, three, and nine cycles of avelumab. Changes in soluble (s) CD27 and sCD40L in plasma were also evaluated. In vitro studies were also performed to determine if avelumab would mediate ADCC of PBMC. Results: No statistically significant changes in any of the 123 immune cell subsets analyzed were observed at any dose level, or number of doses, of avelumab. Increases in the ratio of sCD27:sCD40L were observed, suggesting potential immune activation. Controlled in vitro studies also showed lysis of tumor cells by avelumab versus no lysis of PBMC from five donors. Conclusions: These studies demonstrate the lack of any significant effect on multiple immune cell subsets, even those expressing PD-L1, following multiple cycles of avelumab. These results complement prior studies showing anti-tumor effects of avelumab and comparable levels of adverse events with avelumab versus other anti-PD-1/PD-L1 MAbs. These studies provide the rationale to further exploit the potential ADCC mechanismof action of avelumab as well as other human IgG1 checkpoint inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
24. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.
- Author
-
McNeel, Douglas G., Bander, Neil H., Beer, Tomasz M., Drake, Charles G., Fong, Lawrence, Harrelson, Stacey, Kantoff, Philip W., Madan, Ravi A., Oh, William K., Peace, David J., Petrylak, Daniel P., Porterfield, Hank, Sartor, Oliver, Shore, Neal D., Slovin, Susan F., Stein, Mark N., Vieweg, Johannes, and Gulley, James L.
- Subjects
- *
IMMUNOTHERAPY , *INCURABLE diseases , *PROSTATE cancer - Abstract
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST.
- Author
-
Fenerty, Kathleen E., Folio, Les R., Patronas, Nicholas J., Marté, Jennifer L., Gulley, James L., and Heery, Christopher R.
- Subjects
- *
CHORDOMA , *IMMUNOTHERAPY , *VOLUMETRIC analysis , *TUMORS , *PERPENDICULAR axis theorem , *PATIENTS , *ANTHROPOMETRY , *CLINICAL trials , *COMPARATIVE studies , *GERM cell tumors , *LONGITUDINAL method , *LYMPH nodes , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *SURVIVAL , *TUMOR classification , *EVALUATION research , *TREATMENT effectiveness , *RETROSPECTIVE studies , *TUMOR treatment - Abstract
Background: The Response Evaluation Criteria in Solid Tumors (RECIST) are the current standard for evaluating disease progression or therapy response in patients with solid tumors. RECIST 1.1 calls for axial, longest-diameter (or perpendicular short axis of lymph nodes) measurements of a maximum of five tumors, which limits clinicians' ability to adequately measure disease burden, especially in patients with irregularly shaped tumors. This is especially problematic in chordoma, a disease for which RECIST does not always adequately capture disease burden because chordoma tumors are typically irregularly shaped and slow-growing. Furthermore, primary chordoma tumors tend to be adjacent to vital structures in the skull or sacrum that, when compressed, lead to significant clinical consequences.Methods: Volumetric segmentation is a newer technology that allows tumor burden to be measured in three dimensions on either MR or CT. Here, we compared the ability of RECIST measurements and tumor volumes to predict clinical outcomes in a cohort of 21 chordoma patients receiving immunotherapy.Results: There was a significant difference in radiologic time to progression Kaplan-Meier curves between clinical outcome groups using volumetric segmentation (P = 0.012) but not RECIST (P = 0.38). In several cases, changes in volume were earlier and more sensitive reflections of clinical status.Conclusion: RECIST is a useful evaluation method when obvious changes are occurring in patients with chordoma. However, in many cases, RECIST does not detect small changes, and volumetric assessment was capable of detecting changes and predicting clinical outcome earlier than RECIST. Although this study was small and retrospective, we believe our results warrant further research in this area. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
26. Poxviral-based vaccine elicits immunologic responses in prostate cancer patients.
- Author
-
Madan, Ravi A, Heery, Christopher R, and Gulley, James L
- Subjects
- *
PROSTATE , *CANCER patients , *IMMUNOREGULATION , *IMMUNOTHERAPY ,ALTERNATIVE treatment for immunologic diseases - Abstract
Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients. Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elicits anticancer immune responses, both alone and in combinatorial approaches. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
27. Effects of conventional therapeutic interventions on the number and function of regulatory T cells.
- Author
-
Roselli, Mario, Cereda, Vittore, di Bari, Maria Giovanna, Formica, Vincenzo, Spila, Antonella, Jochems, Caroline, Farsaci, Benedetto, Donahue, Renee, Gulley, James L., Schlom, Jeffrey, and Guadagni, Fiorella
- Subjects
- *
T cells , *ANTINEOPLASTIC agents , *CANCER patients , *DRUG therapy , *IMMUNE system - Abstract
Several lines of investigation have revealed the apparent interplay between the immune system of the host and many conventional, "standard-of-care" anticancer therapies, including chemotherapy and small molecule targeted therapeutics. In particular, preclinical and clinical studies have demonstrated the important role of regulatory T cells (Tregs) in inhibiting immune responses elicited by immunotherapeutic regimens such as those based on anticancer vaccines or checkpoint inhibitors. However, how the number and immunosuppressive function of Tregs change in cancer patients undergoing treatment with non-immune anticancer therapies remains to be precisely elucidated. To determine whether immunostimulatory therapies can be employed successfully in combination with conventional anticancer regimens, we have investigated both the number and function of Tregs obtained from the peripheral blood of carcinoma patients before the initiation and during the course of chemotherapeutic and targeted agent regimens. Our studies show that the treatment of breast cancer patients with tamoxifen plus leuprolide, a gonadotropin releasing hormone agonist, has minimal effects on Tregs, while sunitinib appears to exert differential effects on Tregs among patients with metastatic renal carcinoma. However, the administration of docetaxel to patients with metastatic prostate or breast cancer, as well as that of cisplatin plus vinorelbine to non-small cell lung cancer patients, appears to significantly increase the ratio between effector T cells and Tregs and to reduce the immunosuppressive activity of the latter in the majority of patients. These studies provide the rationale for the selective use of active immunotherapy regimens in combination with specific standard-of-care therapies to achieve the most beneficial clinical outcome among carcinoma patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
28. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.
- Author
-
Jianping Huang, Jochems, Caroline, Talaie, Tara, Anderson, Austin, Jales, Alessandra, Kwong Y. Tsang, Madan, Ravi A., Gulley, James L., and Schlom, Jeffrey
- Subjects
- *
CD40 antigen , *CANCER patients , *BLOOD serum analysis , *CYTOKINES , *TUMOR immunology , *IMMUNOSUPPRESSION , *CELL proliferation - Abstract
Tumor cells can induce certain cytokines and soluble receptors that have a sup-pressive effect on the immune system. In this study, we showed that an extracellu-lar portion of a membrane-bound ligand of CD40 (soluble CD40 ligand; sCD40L) was significantly elevated in the serum of cancer patients compared with healthy donors. In addition, PBMCs from cancer patients had a relatively larger population of myeloid-derived suppressor cells (MDSCs), defined as CD33+HLA-DR cells, and these cells expressed higher levels of CD40. T-cell proliferation and IFN-7 production decreased when stimulated T cells were cocultured with an increased amount of autologous MDSCs. The addi-tion of recombinant monomeric sCD40L enriched MDSCs and had an additive inhibitory effect on T-cell proliferation. PBMCs cultured in vitro with sCD40L also showed an expansion of regulatory T cells (CD4+CD25highFoxp3+), as well as Induction of cytokines, such as IL-10 and IL-6. Moreover, sCD40L-induced enrich-ment of programmed death-1-expressing T cells was greater in cancer patients than in healthy donors. Preexisting sCD40L also Inhibited IL-12 production from monocytes on activation. These data suggest that the higher levels of sCD40L seen in cancer patients may have an immunosuppressive effect. These studies were registered at www.clinicaltrials.gov as NCT00060528, NCT00019695, NCT00179309, NCT00514072, NCT00081848, and NCT00436956. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
29. IgG Responses to Tissue-Associated Antigens as Biomarkers of Immunological Treatment Efficacy.
- Author
-
Smith, Heath A., Maricque, Brett B., Eberhardt, John, Petersen, Benjamin, Gulley, James L., Schlom, Jeffrey, and McNeel, Douglas G.
- Abstract
We previously demonstrated that IgG responses to a panel of 126 prostate tissue-associated antigens are common in patients with prostate cancer. In the current report we questioned whether changes in IgG responses to this panel might be used as a measure of immune response, and potentially antigen spread, following prostate cancer-directed immune-active therapies. Sera were obtained from prostate cancer patients prior to and three months following treatment with androgen deprivation therapy (n = 34), a poxviral vaccine (n = 31), and a DNA vaccine (n = 21). Changes in IgG responses to individual antigens were identified by phage immunoblot. Patterns of IgG recognition following three months of treatment were evaluated using a machine-learned Bayesian Belief Network (ML-BBN).We found that different antigens were recognized following androgen deprivation compared with vaccine therapies. While the number of clinical responders was low in the vaccine-treated populations, we demonstrate that ML-BBN can be used to develop potentially predictive models. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
30. Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer.
- Author
-
Rotow, Julia, Gameiro, Sofia R., Madan, Ravi A., Gulley, James L., Schlom, Jeffrey, and Hodge, James W.
- Subjects
- *
PROSTATE cancer , *CANCER vaccines , *DRUG therapy , *PREVENTIVE medicine - Abstract
Prostate cancer is the second leading cause of cancer death among men in the United States. Standard-of-care chemotherapy for metastatic castration-resistant prostate cancer is associated with significant but modest survival benefit, indicating a need for alternative and/or additional approaches. The use of therapeutic cancer vaccines for the treatment of prostate cancer represents a novel targeted therapeutic approach. Whereas vaccine strategies are being developed for the treatment of various stages of prostate cancer, this article focuses on novel vaccine strategies for castration-resistant prostate cancer that have been translated into late-stage clinical studies. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
31. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
- Author
-
Cereda, Vittore, Poole, Diane J., Palena, Claudia, Das, Sudipto, Bera, Tapan K., Remondo, Cinzia, Gulley, James L., Arlen, Philip M., Yokokawa, Junko, Pastan, Ira, Schlom, Jeffrey, and Tsang, Kwong Y.
- Subjects
- *
PROTEINS , *PROSTATE cancer , *HYPERPLASIA , *EPITOPES , *T cells - Abstract
New gene expressed in prostate (NGEP) is a prostate-specific gene encoding either a small cytoplasmic protein (NGEP-S) or a larger polytopic membrane protein (NGEP-L). NGEP-L expression is detectable only in prostate cancer, benign prostatic hyperplasia and normal prostate. We have identified an HLA-A2 binding NGEP epitope (designated P703) which was used to generate T cell lines from several patients with localized and metastatic prostate cancer. These T cell lines were able to specifically lyse HLA-A2 and NGEP-expressing human tumor cells. NGEP-P703 tetramer binding assays demonstrated that metastatic prostate cancer patients had a higher frequency of NGEP-specific T cells when compared with healthy donors. Moreover, an increased frequency of NGEP-specific T cells was detected in the peripheral blood mononuclear cells of prostate cancer patients post-vaccination with a PSA-based vaccine, further indicating the immunogenicity of NGEP. These studies thus identify NGEP as a potential target for T cell-mediated immunotherapy of prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
32. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.
- Author
-
Vaishampayan, Ulka, Schöffski, Patrick, Ravaud, Alain, Borel, Christian, Peguero, Julio, Chaves, Jorge, Morris, John C., Kotecki, Nuria, Smakal, Martin, Zhou, Dongli, Guenther, Silke, Bajars, Marcis, and Gulley, James L.
- Subjects
- *
RENAL cell carcinoma , *INTRAVENOUS therapy , *PROGRESSION-free survival , *PROGRAMMED cell death 1 receptors , *ANTINEOPLASTIC agents , *METASTASIS , *DRUG efficacy - Abstract
Background: Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial assessed the efficacy and safety of avelumab (anti–PD-L1) monotherapy in patients with mRCC as either first-line (1 L) or second-line (2 L) treatment. Methods: Patients with mRCC with a clear-cell component who were treatment naive (1 L subgroup) or had disease progression after one prior line of therapy (2 L subgroup) received avelumab 10 mg/kg intravenous infusion every 2 weeks. Endpoints included confirmed best overall response, duration of response (DOR), progression-free survival (PFS), overall survival (OS), PD-L1 expression, and safety. Results: A total of 62 patients were enrolled in the 1 L subgroup, and 20 patients were enrolled in the 2 L subgroup. In the 1 L and 2 L subgroups, confirmed objective response rates were 16.1 and 10.0%, median DOR was 9.9 months (95% confidence interval [CI], 2.8–not evaluable) and not evaluable (95% CI, 6.9–not evaluable), median PFS was 8.3 months (95% CI, 5.5–9.5) and 5.6 months (95% CI, 2.3–9.6), and median OS was not evaluable (95% CI, not evaluable) and 16.9 months (95% CI, 8.3–not evaluable), respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 51 patients in the 1 L subgroup (82.3%) and 14 patients in the 2 L subgroup (70.0%). Grade ≥ 3 TRAEs occurred in eight patients in the 1 L subgroup (12.9%) and one patient in the 2 L subgroup (5.0%). No treatment-related deaths occurred. Conclusion: Avelumab showed clinical activity and a manageable safety profile in both the 1 L and 2 L treatment setting in patients with mRCC. These data support the use of avelumab in combination with other agents in mRCC. Trial registration: ClinicalTrials.gov: NCT01772004; registered 21 January, 2013. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
- Author
-
Bilusic, Marijo, Heery, Christopher R., Collins, Julie M., Donahue, Renee N., Palena, Claudia, Madan, Ravi A., Karzai, Fatima, Marté, Jennifer L., Strauss, Julius, Gatti-Mays, Margaret E., Schlom, Jeffrey, and Gulley, James L.
- Subjects
- *
MONOCLONAL antibodies , *CHONDROSARCOMA , *HYPOPHOSPHATEMIA , *SUPPRESSOR cells , *THERAPEUTICS , *CANCER , *CANCER invasiveness - Abstract
Background: HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of myeloid-derived suppressor cells. Studies have demonstrated that high serum IL-8 levels correlate with poor prognosis in many malignant tumors. Preclinical studies have shown that IL-8 blockade may reduce mesenchymal features in tumor cells, making them less resistant to treatment. Methods: Fifteen patients with metastatic or unresectable locally advanced solid tumors were enrolled in this 3 + 3 dose-escalation trial at four dose levels (4, 8, 16, or 32 mg/kg). HuMax-IL8 was given IV every 2 weeks, and patients were followed for safety and immune monitoring at defined intervals up to 52 weeks. Results: All enrolled patients (five chordoma, four colorectal, two prostate, and one each of ovarian, papillary thyroid, chondrosarcoma, and esophageal) received at least one dose of HuMax-IL8. Eight patients had received three or more prior lines of therapy and five patients had received prior immunotherapy. Treatment-related adverse events occurred in five patients (33%), mostly grade 1. Two patients receiving the 32 mg/kg dose had grade 2 fatigue, hypophosphatemia, and hypersomnia. No dose-limiting toxicities were observed, and maximum tolerated dose was not reached. Although no objective tumor responses were observed, 11 patients (73%) had stable disease with median treatment duration of 24 weeks (range, 4–54 weeks). Serum IL-8 was significantly reduced on day 3 of HuMax-IL8 treatment compared to baseline (p = 0.0004), with reductions in IL-8 seen at all dose levels. Conclusions: HuMax-IL8 is safe and well-tolerated. Ongoing studies are evaluating the combination of IL-8 blockade and other immunotherapies. Trial registration: NCTN, NCT02536469. Registered 23 August 2015, https://clinicaltrials.gov/ct2/show/NCT02536469?term=NCT02536469&rank=1. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.
- Author
-
Cardis, Michael A., Jiang, Hong, Strauss, Julius, Gulley, James L., and Brownell, Isaac
- Subjects
- *
MERKEL cell carcinoma , *THERAPEUTICS , *KERATOSIS , *BULLOUS pemphigoid , *LICHEN planus , *DRUG side effects , *VITILIGO - Abstract
Background: Avelumab is an anti-programmed cell death ligand 1 (PD-L1) antibody approved for treatment of Merkel cell carcinoma (MCC) and locally advanced or metastatic urothelial carcinoma. It shares a similar side effect profile to other immune checkpoint inhibitors, including immune-related adverse reactions in the skin. These adverse skin reactions can present as a morbilliform exanthem, lichenoid dermatitis, vitiligo, autoimmune bullous disorder, among others.Case Presentation: We describe a patient with advanced MCC successfully treated with avelumab who developed acute onset diffuse lichen planus-like keratoses (LPLK) at sites of existing seborrheic keratoses (SK) and lentigines. Histopathology of an affected SK revealed papillomatous epidermal hyperplasia with lichenoid interface changes, numerous dyskeratotic keratinocytes and intermittent hypergranulosis. The findings resembled lichen planus (LP) arising in an SK. Onset of the skin symptoms corresponded with an inflammatory cancer response (clinical pseudo-progression), and the eruption improved as overall tumor burden decreased. The patient's pruritus was treated with topical steroids and cyrotherapy for individual symptomatic lesions.Conclusion: Diffuse LPLK is a distinct immune-related reaction pattern associated with PD-L1/PD-1 checkpoint blockade. This is an important side effect to be aware of as LPLK frequently mimic keratinocytic neoplasms. Further observation is needed to assess the prevalence and significance of this immune therapy-associated adverse reaction. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
35. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
- Author
-
Allen, Clint T., Lee, Sunmin, Norberg, Scott M., Kovalovsky, Damian, Ye, Hong, Clavijo, Paul E., Hu-Lieskovan, Siwen, Schlegel, Richard, Schlom, Jeffrey, Strauss, Julius, Gulley, James L., Trepel, Jane, and Hinrichs, Christian S.
- Subjects
- *
PAPILLOMA , *VIRAL load , *THERAPEUTICS , *TREATMENT duration - Abstract
Background: Recurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV)-driven disorder that causes substantial morbidity and can lead to fatal distal airway obstruction and post-obstructive pneumonias. Patients require frequent surgical debridement of disease, and no approved systemic adjuvant therapies exist. Methods: A phase II study was conducted to investigate the clinical activity and safety of programmed death-ligand 1 (PD-L1) blockade with avelumab in patients with RRP. Results: Twelve patients were treated. All patients with laryngeal RRP displayed improvement in disease burden, and 5 of 9 (56%) displayed partial responses. None of 4 patients with pulmonary RRP displayed a response. Using each patient's surgical history as their own control, patients required fewer surgical interventions after avelumab treatment (p = 0.008). A subset of partial responders developed HPV-specific reactivity in papilloma-infiltrating T-cells that correlated with reduced HPV viral load and an increased Tissue Inflammation Signature. Conclusions: Avelumab demonstrated safety and clinical activity in patients with laryngeal RRP. Further study of immune checkpoint blockade for RRP, possibly with longer treatment duration or in combination with other immunotherapies aimed at activating antiviral immunity, is warranted. Trial registration: NCT, number NCT02859454, registered August 9, 2016. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.
- Author
-
Keilholz, Ulrich, Mehnert, Janice M., Bauer, Sebastian, Bourgeois, Hugues, Patel, Manish R., Gravenor, Donald, Nemunaitis, John J., Taylor, Matthew H., Wyrwicz, Lucjan, Lee, Keun-Wook, Kasturi, Vijay, Chin, Kevin, von Heydebreck, Anja, and Gulley, James L.
- Subjects
- *
MELANOMA , *TUMORS , *SUBGROUP analysis (Experimental design) , *PROGRESSION-free survival , *MONOCLONAL antibodies , *CANCER treatment , *METASTASIS , *DRUG side effects - Abstract
Background: We report phase 1b data from patients enrolled in the JAVELIN Solid Tumor clinical trial (NCT01772004) with unresectable stage IIIC or IV melanoma that had progressed after ≥1 line of therapy for metastatic disease. Patients and methods: Patients received avelumab (10 mg/kg)—a human anti–PD-L1 antibody. Assessments included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Results: As of December 31, 2016, 51 patients were treated and followed for a median of 24.2 months (range, 16.1–31.5). Most patients had cutaneous (n = 28 [54.9%]) or ocular (n = 16 [31.4%]) melanoma and had received a median of 2 prior lines of therapy (range, 0–4), including ipilimumab (n = 26 [51.0%]). The confirmed ORR was 21.6% (95% CI, 11.3–35.3; complete response, 7.8%; partial response, 13.7%). The median duration of response was not estimable (95% CI, 2.6 months-not estimable). Median PFS and OS were 3.1 months (95% CI, 1.4–6.3) and 17.2 months (95% CI, 6.6-not estimable), respectively. Subgroup analyses suggested meaningful clinical activity (ORR [95% CI]) in patients with non-ocular melanoma (31.4% [16.9–49.3]), PD-L1–positive tumors (42.1% [20.3–66.5]), or prior ipilimumab therapy (30.8% [14.3–51.8]). Thirty-nine patients (76.5%) had a treatment-related adverse event (TRAE), most commonly infusion-related reaction (29.4%), fatigue (17.6%), and chills (11.8%); 4 patients (7.8%) had a grade 3 TRAE. Five patients (9.8%) had an immune-related TRAE (all were grade 1/2). No grade 4 TRAEs or treatment-related deaths were reported. Conclusion: Avelumab showed durable responses, promising survival outcomes, and an acceptable safety profile in patients with previously treated metastatic melanoma. Trial registration: ClinicalTrials.gov identifier: NCT01772004. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
- Author
-
Monge, Cecilia, Maeng, Hoyoung, Brofferio, Alessandra, Apolo, Andrea B., Sathya, Bharath, Arai, Andrew E., Gulley, James L., and Bilusic, Marijo
- Subjects
- *
CASTRATION-resistant prostate cancer , *MYOCARDITIS , *CORONARY disease , *TROPONIN I , *CANCER vaccines , *TRAPEZIUS muscle - Abstract
Background: Immune checkpoint inhibitors have revolutionized treatment and improved survival in many cancers. However, since immune-related adverse events (irAEs) are potentially fatal, early recognition and prompt treatment are warranted. One of the rarest but most dramatic irAE is myocarditis, which has significant morbidity and mortality if not recognized and treated early. Objective: To report the first case of myocarditis in a patient with metastatic castration-resistant prostate cancer (mCRPC) treated with a combination of nivolumab, an anti-programmed cell death protein 1 antibody, and PROSTVAC, a vector-based therapeutic prostate cancer vaccine. Case Report: A 79-year-old man with mCRPC metastatic to bone and lymph nodes and a history of atrial fibrillation presented with blurred vision and pain and stiffness in the upper back after 8 weeks on a clinical trial with nivolumab (1 mg/kg) and PROSTVAC, both given every 2 weeks. Eye exam was within normal limits, while musculoskeletal exam revealed tenderness in trapezius muscles and decreased motor strength in arms (III/V) and neck (IV/V). The rest of the physical exam was within normal limits, with the exception of an irregular heart rhythm. Laboratory tests were as follows: creatinine kinase (CK) 3200 U/L (normal: 39–308 U/L), CK-MB 65.7 mcg/L (normal: 0–7.6 mcg/L), troponin I 0.209 ng/mL (normal: 0–0.056 ng/mL). Electrocardiogram (ECG) revealed atrial fibrillation with QT prolongation (QTc 514 msec) and left anterior fascicular block, unchanged from baseline. 2D-echocardiogram showed a left ventricular ejection fraction of 65% with an enlarged left atrium, dilated right ventricle, and increased pulmonary artery pressure (45 mmHg). ProBNP was elevated at 1463 pg/mL and peaked at 3066 pg/mL one day after hydration. With a presumed diagnosis of autoimmune myositis and possible myocarditis, the patient was admitted and started on methylprednisolone 1 mg/kg/day. Cardiac MRI showed elevated native myocardial T1 values consistent with myocarditis (Fig. 1). The patient was discharged on a prednisone taper after normalization of cardiac enzymes on day 4. Treatment with PROSTVAC continued for three more months; nivolumab was discontinued. Six months later, patient is doing well, with no residual cardiac damage. Discussion: Cardiovascular irAEs are relatively rare (< 1%) and have a variety of clinical presentations. Myocarditis is potentially life-threatening and can range from subclinical to fulminant. Therefore, clinical suspicion, early detection, and prompt treatment are imperative (1). The initial diagnostic workup should include cardiac enzymes, ECG, and 2D-echocardiogram. The most commonly observed ECG changes are generalized repolarization abnormalities, prolonged QT interval, and conduction abnormalities (2). An elevated troponin I in the absence of overt coronary artery disease is suggestive of myocarditis and should be evaluated further. Myocardial biopsy is the standard diagnostic procedure; however, a cardiac MRI can achieve a diagnosis when biopsy is not feasible (3). Advancements in parametric mapping techniques have allowed the use of native myocardial T1 in the detection of myocarditis, as it has superior diagnostic performance and higher sensitivity than older parameters (3). Our patient had been treated with an immune checkpoint inhibitor and a therapeutic cancer vaccine to induce effective antitumor activity through immunogenic intensification and presented with muscle stiffness and elevated CK. Although he had no new cardiovascular symptoms, cardiac enzymes were tested to rule out myocardial involvement. MRI with gadolinium confirmed the diagnosis of myocarditis. To date, none of the 1360 patients treated with PROSTVAC as a single agent have developed myocarditis, while myocarditis has been rarely reported in patients treated with nivolumab (< 1%) (1). Whether the combination of PROSTVAC and nivolumab presents an additional risk of myocarditis is unclear. To our knowledge, this is the first case of myocarditis in a patient with mCRPC receiving simultaneous treatment with an immune checkpoint inhibitor and a prostate cancer vaccine. Our experience highlights the importance of suspicion and early intervention in patients who present with cardiac abnormalities after receiving cancer immunotherapy. We propose following protocol: baseline troponin, ECG, and 2D-echocardiogram prior to treatment, then repeated troponin at 2, 4, and 12 weeks post-treatment, then monthly. If troponin becomes positive without alternative explanation, myocarditis should be ruled out with cardiac MRI or myocardial biopsy, and patient should be admitted for treatment with high-dose steroids as early intervention may minimize myocardial injury. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
38. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.
- Author
-
Le Tourneau, Christophe, Hoimes, Christopher, Zarwan, Corrine, Wong, Deborah J., Bauer, Sebastian, Claus, Rainer, Wermke, Martin, Hariharan, Subramanian, von Heydebreck, Anja, Kasturi, Vijay, Chand, Vikram, and Gulley, James L.
- Subjects
- *
TUMOR immunology , *DRUG efficacy , *MEDICATION safety - Abstract
Background: We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC). Methods: In this phase 1b expansion cohort, patients with mACC and prior platinum-based therapy received avelumab at 10 mg/kg intravenously every 2 weeks. Continuation of mitotane was permitted; however, mitotane levels during the study were not recorded. Tumor response was assessed by Response Evaluation Criteria In Solid Tumors v1.1. Results: Fifty patients received avelumab and were followed for a median of 16.5 months. Prior treatment included ≥2 lines in 74.0%; mitotane was continued in 50.0%. The objective response rate (ORR) was 6.0% (95% CI, 1.3% to 16.5%; partial response in 3 patients). Twenty-one patients (42.0%) had stable disease as best response (disease control rate, 48.0%). Median progression-free survival was 2.6 months (95% CI, 1.4 to 4.0), median overall survival (OS) was 10.6 months (95% CI, 7.4 to 15.0), and the 1-year OS rate was 43.4% (95% CI, 27.9% to 57.9%). In evaluable patients with PD-L1+ (n = 12) or PD-L1− (n = 30) tumors (≥5% tumor cell cutoff), ORR was 16.7% vs 3.3% (P =.192). Treatment-related adverse events (TRAEs) occurred in 82.0%; the most common were nausea (20.0%), fatigue (18.0%), hypothyroidism (14.0%), and pyrexia (14.0%). Grade 3 TRAEs occurred in 16.0%; no grade 4 to 5 TRAEs occurred. Twelve patients (24.0%) had an immune-related TRAE of any grade, which were grade 3 in 2 patients (4.0%): adrenal insufficiency (n = 1), and pneumonitis (n = 1). Conclusions: Avelumab showed clinical activity and a manageable safety profile in patients with platinum-treated mACC. Trial registration: Clinicaltrials.gov NCT01772004; registered January 21, 2013. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
39. White paper on microbial anti-cancer therapy and prevention.
- Author
-
Forbes, Neil S., Coffin, Robert S., Deng, Liang, Evgin, Laura, Fiering, Steve, Giacalone, Matthew, Gravekamp, Claudia, Gulley, James L., Gunn, Hal, Hoffman, Robert M., Kaur, Balveen, Liu, Ke, Lyerly, Herbert Kim, Marciscano, Ariel E., Moradian, Eddie, Ruppel, Sheryl, Saltzman, Daniel A., Tattersall, Peter J., Thorne, Steve, and Vile, Richard G.
- Subjects
- *
CANCER treatment , *ANTINEOPLASTIC agents , *DRUG development - Abstract
In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National Cancer Institute in the summer of 2017. Here, we define 'Microbial Therapy' to include both oncolytic viral therapy and bacterial anticancer therapy. Both of these fields exploit tumor-specific infectious microbes to treat cancer, have similar mechanisms of action, and are facing similar challenges to commercialization. We designed this paper to nucleate this growing field of microbial therapeutics and increase interactions between researchers in it and related fields. The authors of this paper include many primary researchers in this field. In this paper, we discuss the potential, status and opportunities for microbial therapy as well as strategies attempted to date and important questions that need to be addressed. The main areas that we think will have the greatest impact are immune stimulation, control of efficacy, control of delivery, and safety. There is much excitement about the potential of this field to treat currently intractable cancer. Much of the potential exists because these therapies utilize unique mechanisms of action, difficult to achieve with other biological or small molecule drugs. By better understanding and controlling these mechanisms, we will create new therapies that will become integral components of cancer care. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
40. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
- Author
-
Boyiadzis, Michael M., Kirkwood, John M., Marshall, John L., Pritchard, Colin C., Azad, Nilofer S., and Gulley, James L.
- Subjects
- *
DRUG approval , *PEMBROLIZUMAB , *BIOLOGICAL tags - Abstract
The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agnostic FDA approval of a treatment based on a patient's tumor biomarker status, rather than on tumor histology. Here we discuss key issues and implications arising from the biomarker-based disease classification implied by this historic approval. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
41. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.
- Author
-
David, Justin M., Dominguez, Charli, McCampbell, Kristen K., Gulley, James L., Schlom, Jeffrey, and Palena, Claudia
- Subjects
- *
MESENCHYME tumors , *LUNG cancer , *PROGRAMMED cell death 1 receptors - Abstract
Mesenchymalization is a cellular and molecular program in which epithelial cells progressively lose their well-differentiated phenotype and adopt mesenchymal characteristics. Tumor mesenchymalization occurs during the progression of cancer to metastatic disease, and is also associated with resistance to multiple therapeutics, including killing by cytotoxic immune cells. Furthermore, tumor cells can evade immune destruction by upregulating the checkpoint molecule PD-L1, and emerging research has found higher PD-L1 expression in mesenchymalized tumors. Here, the association between TGF-β1-mediated mesenchymalization and PD-L1 was investigated in non-small cell lung cancer cells (NSCLC). TGF-β1 was found to upregulate PD-L1 gene transcription in a Smad2-dependent manner, and a positive association between PD-L1 and phosphorylated Smad2 was found in NSCLC tumors. The potential to target these 2 negative immune regulators with a single agent was investigated using M7824, a novel clinical-stage bifunctional agent that targets both PD-L1 and TGF-β. Treatment of NSCLC cells with M7824in vitroandin vivoattenuated features of TGF-β1-mediated mesenchymalization, including mesenchymal marker expression, proliferation suppression, and chemoresistance. These findings demonstrate that upregulation of tumor cell PD-L1 is a novel mechanism of TGF-β1-induced immunosuppression in NSCLC, and that treatment with M7824 has the potential to simultaneously block both tumor mesenchymalization and PD-L1-dependent immunosuppression. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
42. TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.
- Author
-
Wood, Lauren V., Fojo, Antonio, Roberson, Brenda D., Hughes, Meghan S. B., Dahut, William, Gulley, James L., Madan, Ravi A., Arlen, Philip M., Sabatino, Marianna, Stroncek, David F., Castiello, Luciano, Trepel, Jane B., Lee, Min-Jung, Parnes, Howard L., Steinberg, Seth M., Terabe, Masaki, Wilkerson, Julia, Pastan, Ira, and Berzofsky, Jay A.
- Subjects
- *
T-cell receptor genes , *GENES , *BREAST cancer , *PROSTATE cancer , *TUMOR growth - Abstract
T-cell receptor alternate reading frame protein (TARP) is a 58-residue protein over-expressed in prostate and breast cancer. We investigated TARP peptide vaccination's impact on the rise in PSA (expressed as Slope Log(PSA) or PSA Doubling Time (PSADT)), validated tumor growth measures, and tumor growth rate in men with Stage D0 prostate cancer. HLA-A*0201 positive men were randomized to receive epitope-enhanced (29-37-9V) and wild-type (27-35) TARP peptides administered as a Montanide/GM-CSF peptide emulsion or as an autologous peptide-pulsed dendritic cell vaccine every 3 weeks for a total of five vaccinations with an optional 6th dose of vaccine at 36 weeks based on immune response or PSADT criteria with a booster dose of vaccine for all patients at 48 and 96 weeks. 41 patients enrolled with median on-study duration of 75 weeks at the time of this analysis. Seventy-two percent of patients reaching 24 weeks and 74% reaching 48 weeks had a decreased Slope Log(PSA) compared to their pre-vaccination baseline (p= 0.0012 andp= 0.0004 for comparison of overall changes in Slope Log(PSA), respectively). TARP vaccination also resulted in a 50% decrease in median tumor growth rate (g): pre-vaccineg= 0.0042/day, post-vaccineg= 0.0021/day (p= 0.003). 80% of subjects exhibited new vaccine-induced TARP-specific IFNγ ELISPOT responses but they did not correlate with decreases in Slope Log(PSA). Thus, vaccination with TARP peptides resulted in significant slowing in PSA velocity and reduction in tumor growth rate in a majority of patients with PSA biochemical recurrence. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
43. IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy.
- Author
-
Smith, Heath A, Maricque, Brett B, Eberhardt, John, Petersen, Benjamin, Gulley, James L, Schlom, Jeffrey, and McNeel, Douglas G
- Abstract
We previously demonstrated that IgG responses to a panel of 126 prostate tissue-associated antigens are common in patients with prostate cancer. In the current report we questioned whether changes in IgG responses to this panel might be used as a measure of immune response, and potentially antigen spread, following prostate cancer-directed immune-active therapies. Sera were obtained from prostate cancer patients prior to and three months following treatment with androgen deprivation therapy (n = 34), a poxviral vaccine (n = 31), and a DNA vaccine (n = 21). Changes in IgG responses to individual antigens were identified by phage immunoblot. Patterns of IgG recognition following three months of treatment were evaluated using a machine-learned Bayesian Belief Network (ML-BBN). We found that different antigens were recognized following androgen deprivation compared with vaccine therapies. While the number of clinical responders was low in the vaccine-treated populations, we demonstrate that ML-BBN can be used to develop potentially predictive models. [ABSTRACT FROM AUTHOR]
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.